Search clinical trials for: BI 1060469 Healthy

Total 8294 results

Boehringer Ingelheim

Completed

4 Week Combination of BI 207127 NA With Peg-IFN and Ribavirin in Chronic HCV Patients

Hepatitis C, Chronic

France, Germany, Switzerland
Texas Tech University

Completed

Healthy Online Parental Education Project to Increase Fruit and Vegetable Intake and Active Playtime Among Toddlers (HOPE)

Eating Behavior

United States
Boehringer Ingelheim

Terminated

A Study to Test Whether Two Different Doses of Avenciguat Help People With Liver Cirrhosis and High Blood Pressure in the Portal Vein (Main Vessel Going to the Live

Hypertension, Portal

Spain, Denmark, United Kingdom, Singapore, Germany, Italy, Austria, Taiwan, Canada, Croatia, China, Netherlands, Belgium, United States, Japan, Argentina, France, Switzerland, Portugal, Israel, Romania, Korea, Republic of
Evangelismos Hospital
Sotiria General Hospital; Elpis General Hospital; Evgenidion Hospital

Completed

Bi-PAP vs Sham Bi-PAP on Pulmonary Function in Morbidly Obese Patients After Bariatric Surgery

Morbid Obesity | Pulmonary Disease | Chronic Obstructive Pulmonary Disease (COPD) | Hypoxemia | Hypoxemic Respiratory Failure | Atelectasis | Pulmonary Infection
Boehringer Ingelheim

Completed

A Study in Healthy People to Compare 2 Different Formulations of BI 1358894 Tablets Taken With or Without Food

Healthy

Germany
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 11634 Solution in Healthy Male Volunteers

Healthy
Alzheimer's Disease Expert Lab (ADEL), Inc.
Oscotec Inc.

Recruiting

A Phase Ia/Ib, First-in-human (FIH) Study for Safety, Tolerability, Pharmacokinetics (PK), and Clinical Activity Evaluation of ADEL-Y01

Alzheimer Disease

United States
Boehringer Ingelheim
Eli Lilly and Company

Completed

Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Background Metformin in Patient With Type 2 Diabetes

Diabetes Mellitus, Type 2

United States, Argentina, Australia, Canada, El Salvador, Germany, Italy, Portugal, Russian Federation, Spain, Ukraine
Supplement Formulators, Inc.

Completed

Study to Evaluate the Effects of a Weight Management Program on Body Weight

Body Weight

United States
University Health Network, Toronto
Canadian Cancer Society (CCS)

Completed

Strategies to Improve Bone Health in Men on ADT

Prostate Cancer

Canada
University of Michigan
Mahidol University; Fogarty International Center of the National Institute...

Completed

The Adaptation, Usability, and Feasibility of a Mobile Health (mHealth) System to Improve Type 2 Diabetes Self-management in Thailand

Type 2 Diabetes Mellitus

Thailand
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Mono Products of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Boehringer Ingelheim

Completed

Safety, Tolerability and Pharmacokinetics of the Fixed Dose Combination of BI 1744 CL Plus BI 54903 XX Via Respimat® B Versus the Free Combination of BI 1744 CL Via Respimat® A and BI 54903 XX Via Respimat® B in Healthy Male and Female Volunteers

Healthy
Wollo University

Recruiting

Interactive Mobile Health Intervention to Improve Early Postpartum Modern Contraceptive Method Uptake (EPPMC)

Other Cardiovascular Diseases of Mother, Postpartum

Ethiopia
Boehringer Ingelheim

Completed

A Study to Investigate the Efficacy, Safety and Tolerability of Four Different Doses of BI 409306 Compared to Placebo Given for 12 Weeks in Patients With Schizophrenia on Stable Antipsychotic Treatment.

Schizophrenia

United States, Taiwan, Germany, Japan, Canada
Eskisehir Osmangazi University

Completed

Effect of Motivational Interviews on Cardiovascular Disease Risks and Healthy Lifestyle Behavior Changes

Essential Hypertension | Cardiovascular Disease Risk | Motivational Interview | Healthy Lifestyle Behavior

Turkey
Massachusetts General Hospital
Massachusetts Institute of Technology

Unknown

An Integrated Closed-loop Feedback System for Pediatric Cardiometabolic Disease (STRIVE)

Obesity | Health Behavior
Boehringer Ingelheim

Recruiting

A Study to Test Whether Survodutide (BI 456906) Helps People Living With Overweight or Obesity Who Also Have Diabetes to Lose Weight (SYNCHRONIZE™-2)

Obesity | Diabetes Mellitus, Type 2

United States, Korea, Republic of, Belgium, Spain, China, Australia, Hungary, Canada, Czechia, Poland, New Zealand, Denmark, Finland, Germany, Greece, Netherlands, Sweden, Japan, United Kingdom
Boehringer Ingelheim

Completed

A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease

Chronic Kidney Disease

Spain, Canada, Australia, United States, Japan, Malaysia, United Kingdom, China, Mexico, Denmark, Russian Federation, Germany, Portugal, Hong Kong, Poland, Argentina, New Zealand, Sweden
Boehringer Ingelheim

Completed

A Study of BI 765128 in Patients With an Eye Condition Called Diabetic Macular Ischemia Who Have Received Laser Treatment (PARTRIDGE)

Diabetic Retinopathy

Spain, United Kingdom, United States, Netherlands, Australia, Latvia
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How Well Different Doses of BI 1819479 Are Tolerated

Healthy

Japan
Alkahest, Inc.

Completed

Evaluate the Therapeutic Effects and Safety of ALK4290 in Patients With Refractory Wet Age-Related Macular Degeneration

Wet Age-related Macular Degeneration

Hungary
Boehringer Ingelheim

Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Rising Oral Doses of BI 14332 CL Powder in Healthy Male Subjects

Healthy
Boehringer Ingelheim

Completed

BI 2536 BS in Patients With Advanced Solid Tumours and Repeated Administration in Patients With Clinical Benefit

Neoplasms
Boehringer Ingelheim

Terminated

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 1291583 is Processed in the Body

Healthy

Netherlands
Boston Medical Center
Boston University; National Institute on Drug Abuse (NIDA); RTI International

Completed

Assessing Screening Plus Brief Intervention's Resulting Efficacy (ASPIRE) to Stop Drug Use (ASPIRE)

Drug Abuse | Drug Usage | Drug Dependence

United States
Boehringer Ingelheim

Completed

Clinical Drug Trial in Healthy Male Subjects to Determine and Compare the Blood Concentrations of BI 144807 Following Administration as Oral Solution and Tablet Under Fasted and Fed Conditions

Healthy

Germany
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 730357 is Processed by the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Metabolism and Pharmacokinetics of [14C]-BI 409306 After Administration as Oral Solution in Healthy Male Volunteers

Healthy

United Kingdom
AbbVie

No longer available

Expanded Access to Risankizumab

Crohn's Disease | Ulcerative Colitis (UC)
University of Reading
Danisco

Completed

A Study of a Prebiotic, a Probiotic and a Synbiotic Upon the Gut Microbiota and Immune Response of Healthy Volunteers (XOS)

Gut Microbiota | Immune Function | Bowel Function | Plasma Lipids

United Kingdom
William Beaumont Hospitals
Haines, David MD

Completed

Biventricular Pacing In Patients With Left Ventricular Dysfunction After Cardiovascular Surgery

Thoracic Surgery | Heart Failure, Congestive | Cardiomyopathy

United States
University of California, San Diego
National Institutes of Health (NIH); National Institute on Aging (NIA)

Terminated

Independent Walking for Brain Health

Physical Activity | Aging

United States
Boehringer Ingelheim

Completed

Japanese Pegylated Interferon (PegIFN) Alfa-2b/Ribavirin (RBV) Combination Trial

Hepatitis C

Japan
Boehringer Ingelheim

Recruiting

A Study to Test the Effect of Survodutide (BI 456906) on Cardiovascular Safety in People With Overweight or Obesity (SYNCHRONIZE™ - CVOT)

Obesity

United States, Korea, Republic of, Belgium, Australia, United Kingdom, Mexico, Spain, Germany, Taiwan, Netherlands, Brazil, Hungary, Denmark, Canada, Poland, Austria, China, Finland, Greece, Italy, Hong Kong, Czechia, Portugal, Saudi... and more
Assiut University
WGEKHALEEL; AARMHUSSIEN

Recruiting

HFNC in Management of Bronchiectasis Exacerbation

Bronchiectasis

Egypt
Boehringer Ingelheim

Recruiting

A Study in People With Systemic Sclerosis to Test Whether Avenciguat (BI 685509) Has an Effect on Lung Function and Other Systemic Sclerosis Symptoms (VITALISScE™)

Scleroderma, Systemic

United States, Belgium, Korea, Republic of, Australia, China, Taiwan, Spain, Israel, Japan, Mexico, Turkey, Germany, Italy, Brazil, France, Singapore, India, Philippines, United Kingdom, Switzerland, Finland, Greece, New Zealand, Denmark and more
Boehringer Ingelheim

Recruiting

A Study to Determine How BI 907828 (Brigimadlin) is Taken up in the Tumor (Phase 0) and to Determine the Highest Dose of BI 907828 (Brigimadlin) That Could be Tolerated (Phase 1a) in Combination With Radiation Therapy in People With a Brain Tumor Called Glioblastoma

Glioblastoma

Belgium, Spain, United States
Universitat Jaume I

Not yet recruiting

Blended Treatment for Problem Gambling and Gambling Disorder Combining Group Sessions and Online Modules

Gambling Disorder | Problem Gambling

Spain
Boehringer Ingelheim

Completed

A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight

Obesity

Belgium, Australia, Sweden, United States, Canada, Germany, Korea, Republic of, China, Netherlands, New Zealand, United Kingdom, Poland
Boehringer Ingelheim

Completed

A Study in Healthy Men to Test How BI 456906 is Processed in the Body

Healthy

Netherlands
Boehringer Ingelheim

Completed

Phase I Dose Escalation of i.v. BI 836909 Monotherapy in Last Line Multiple Myeloma Patients

Multiple Myeloma

Germany, France
Boehringer Ingelheim

Completed

Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks

Migraine Disorders

Belgium, Germany
Stereotaxis

Terminated

MAGNET CRT Feasibility - Efficiency of LV Lead Placement Comparing Conventional vs. Magnetic Guidance

Cardiac Resynchronization Therapy

United States
Beijing Tiantan Hospital

Completed

Treatment of Acute Ischemic STroke With Edaravone Dexborneol II (TASTE-2)

Acute Ischemic Stroke | Mechanical Thrombectomy | Edaravone Dexborneol | Phase III

China
Boehringer Ingelheim

Completed

To Investigate the Safety, Tolerability, Pharmacokinetics and the Relative Bioavailability of BI 1026706

Healthy

Germany
Boehringer Ingelheim

Completed

4 Week Treatment With Three Oral Doses of BI 10773 in Patients With Type 2 Diabetes

Diabetes Mellitus, Type 2

Germany
Boehringer Ingelheim

Completed

Bioavailability of Soft Gelatin Capsule Formulation of BI 201335 NA Compared to the Solution Formulation in Healthy Volunteers

Healthy
Boehringer Ingelheim

Active, not recruiting

A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer

Head and Neck Squamous Cell Carcinoma (HNSCC)

Spain, United States, United Kingdom, France, Thailand, Malaysia, Mexico, Romania, Poland, Japan, Moldova, Republic of

3

Subscribe